Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Recurrent Lung Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Cyclophosphamide 30Vincristine 22Rituximab 19Etoposide 19Prednisone 18Filgrastim 16Doxorubicin 16Cytarabine 16Methotrexate 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13merphos 11Leucovorin 11blinatumomab 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Dexamethasone 10azathiopurine 9Specimen Handling 9Methylprednisolone 9Calcium Dobesilate 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Cyclosporine 8prednylidene 7pegaspargase 7fludarabine phosphate 7deltacortene 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Burkitt Lymphoma × sapanisertib × Clear all
NCT02484430 2025-03-03

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡